Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, presents results from the Phase III ZUMA-7 trial (NCT03391466) which assessed axicabtagene ciloleucel (axi-cel), an autologous anti‑CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). 359 patients either received axi-cel or the standard of care, with the primary endpoint being event-free survival (EFS). After a 24 month follow-up, patients in the axi-cel arm demonstrated a superior EFS and overall response rate (ORR). Overall survival (OS) was additionally superior in the axi-cel arm, but was not statistically significant. The results suggest axi-cel can be a second-line treatment for r/r LBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York City, NY, discusses the results from a study making an indirect treatment comparison of adjuvant nivolumab versus placebo in patents with high-risk resected melanoma. This analysis used data from the phase III CheckMate 238 (NCT02388906) trial comparing nivolumab and ipilimumab and from the EORTC 18071 trial (NCT00636168) comparing ipilimumab vs placebo. Results showed that nivolumab was associated with clinically meaningful improvements in recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) in comparison to placebo in this patient population. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, describes the results from the FOCUS4-N trial (EudraCT Number: 2012-005111-12) investigating oral maintenance capecitabine in patients with metastatic colorectal cancer as opposed to capecitabine and bevacizumab, the standard of care, in colorectal cancer. Patients in the FOCUS4-N trial either received capecitabine monotherapy or a treatment break as defined in the COIN trial (NCT00182715). The primary endpoint of progression-free survival (PFS) was met in patients receiving capecitabine. Dr Seligmann additionally discusses whether PFS or overall survival (OS) is the superior primary endpoint in maintenance trials. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.